SEC Comment Letter 0000000000-23-007847 to Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)

Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)
Date: July 24, 2023 · CIK: 0001610618 · Accession: 0000000000-23-007847

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-36912

Date

July 24, 2023

Author

Preetam Shah

Form

UPLOAD

Company

Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)

Letter

United States securities and exchange commission logo July 24, 2023 Preetam Shah Chief Financial Officer Cidara Therapeutics, Inc. 6310 Nancy Ridge Dr, Suite 101 San Diego, CA 92121 Re:Cidara Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2022 Filed March 23, 2023 File No. 001-36912 Dear Preetam Shah: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
July 24, 2023
Preetam Shah
Chief Financial Officer
Cidara Therapeutics, Inc.
6310 Nancy Ridge Dr, Suite 101
San Diego, CA 92121
Re:Cidara Therapeutics, Inc.
Form 10-K for the fiscal year ended December 31, 2022
Filed March 23, 2023
File No. 001-36912
Dear Preetam Shah:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io